We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session Item

Clinical track: Lower GI (colon, rectum, anus)
9306
Poster
Clinical
00:00 - 00:00
EFFECT OF NEOADJUVANT RADIOCHEMOTHERAPY ON ACTIVITY OF PARAOXONASE -1 IN RECTAL CANCER PATIENTS
PO-1104

Abstract

EFFECT OF NEOADJUVANT RADIOCHEMOTHERAPY ON ACTIVITY OF PARAOXONASE -1 IN RECTAL CANCER PATIENTS
Authors: Rodríguez|, Elisabet(1,2);Gomez|, Junior(1);Moreno|, Alazne (2);ACOSTA|, Johana(1)*[johanacacostaa@gmail.com];Torres|, Laura (1);Trilla|, Jordi(1);López|, Yolanda (1);Baiges|, Gerard(2);Hernández|, Anna(2);Camps|, Jordi(2);Joven|, Jorge(2);Arenas|, Meritxell(1,2);
(1)Hospital Universitari Sant Joan de Reus, Department of Radiation Oncology, Reus, Spain;(2)Institut d’Investigació Sanitària Pere Virgili- Universitat Rovira i Virgili, Unitat de Recerca Biomèdica, Reus, Spain;
Show Affiliations
Purpose or Objective

Standard treatment for stage II and III rectal cancer (RC) is neoadjuvant or preoperatively radiochemotherapy (NRCT) followed by surgery. However, little is known about the effects produced by this oncological therapy on paraoxonase-1 (PON1), an antioxidant enzyme. The main objective of the project was to investigate changes in PON1 concentrations and activities, before and one month after NRCT administration in RC patients

Material and Methods

Thirty-two patients with locally advanced RC had been included in the study between 2014 and 2018. Blood samples were collected before and one month after NRCT. PON1 serum concentration was determined, as well as, PON and arylesterase activities. All statistical calculations and graph representations were performed with the statistical package for social sciences (SPSS 22.0, Chicago, IL, USA) and GraphPad Prism 6.01 (GraphPad Software, San Diego, CA, USA).

Results

When compared to healthy controls, PON1 concentration was decreased significantly in patients with RC and it increased one month after receiving the NRCT. Arylesterase activity was also decreased in patients with cancer and further decreased after the treatment. Conversely, PON activity was increased in cancer patients and, showed a non-significant trend to decrease after NRCT (figure 1). Moreover, PON1 concentration and its specific activities were able to differentiate patients with clinical nodal stages N1 and N2 diagnosis

Conclusion

NRCT is able to modify the PON1-related variables in RC patients. One month after NRCT, values of PON1 concentration and enzymatic specific activities are able to return to similar values to those in control individuals. Moreover PON1 concentration and its specific activities could help in the diagnosis of clinical nodal stage.